Inovio Pharmaceuticals, Inc. (NASDAQ:INO) [Trend Analysis] luring active investment momentum, shares a loss -1.71% to $6.91. Inovio Pharmaceuticals, Inc. (INO) revealed that its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody responses in a first-in-man, multi-center phase I trial. In initial testing, Zika-naïve subjects in both low dose and high dose vaccine groups demonstrated Zika antigen-specific antibody responses after one or two vaccinations.
In addition, the vaccine was well tolerated and no important safety concerns were noted in any of the 40 subjects out to 14 weeks from initiation of dosing, the latest accessible data from the study.This phase I, open-label, dose-ranging study of GLS-5700 in healthy adult volunteers is evaluating the safety, tolerability and induction and persistence of Zika specific antibody and T cell responses out to 60 weeks. In preclinical testing Inovio’sZika vaccine protected animals that had been exposed to the virus from infection, brain damage and death. The total volume of 1.07 Million shares held in the session was surprisingly higher than its average volume of 1047.25 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 29.90%, and looking further price to next year’s EPS is -18.80%. While take a short look on price to sales ratio, that was 15.92.
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) [Trend Analysis] runs in leading trade, it plunging -6.50% to traded at $14.24. The firm has price volatility of 7.52% for a week and 5.65% for a month. Its beta stands at 0.68 times. Lexicon Pharmaceuticals, Inc. (LXRX) declared that its pivotal inTandem2 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically important reduction in A1C at 24 weeks in patients with type 1 diabetes on optimized insulin therapy.
Top-line results from the Phase 3 study showed that patients treated with sotagliflozin had mean A1C reductions from baseline of 0.39% on 200mg once daily sotagliflozin dose (p<0.001) and 0.37% on 400mg once daily sotagliflozin dose (p<0.001) as compared to a reduction of 0.03% on placebo after 24 weeks of treatment, meeting the study’s primary endpoint. This statistically important and clinically meaningful improvement in A1C for both doses of sotagliflozin was achieved with a favorable overall safety profile in the study, including rates of severe hypoglycemia similar to placebo and low overall rates of diabetic ketoacidosis (DKA). Narrow down four to firm performance, its weekly performance was -1.23% and monthly performance was -7.53%. The stock price of LXRX is moving down from its 20 days moving average with -10.15% and isolated negatively from 50 days moving average with -10.54%.